The application and research progress of anti-angiogenesis therapy in tumor immunotherapy

Tumor immunotherapy, as the focus of scientific research and clinical tumor treatment in recent years, has received extensive attention. Due to its remarkable curative effect and fewer side effects than traditional treatments, it has significant clinical benefits for the treatment of various advance...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2023-06, Vol.14, p.1198972-1198972
Main Authors: Tu, Jingyao, Liang, Hang, Li, Chunya, Huang, Yongbiao, Wang, Ziqi, Chen, Xinyi, Yuan, Xianglin
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - pharmacology
anti-angiogenesis therapy
Humans
Immunology
Immunotherapy
immunotherapy resistance
Neoplasms - pathology
Neovascularization, Pathologic
tumor immunotherapy
Tumor Microenvironment
vascular normalization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor immunotherapy, as the focus of scientific research and clinical tumor treatment in recent years, has received extensive attention. Due to its remarkable curative effect and fewer side effects than traditional treatments, it has significant clinical benefits for the treatment of various advanced cancers and can improve cancer patient survival in the long term. Currently, most patients cannot benefit from immunotherapy, and some patients may experience tumor recurrence and drug resistance even if they achieve remission overcome. Numerous studies have shown that the abnormal angiogenesis state of tumors can lead to immunosuppressive tumor microenvironment, which affects the efficacy of immunotherapy. Actually, to improve the efficacy of immunotherapy, the application of anti-angiogenesis drugs to normalize abnormal tumor vessel has been widely confirmed in basic and clinical research. This review not only discusses the risk factors, mechanisms, and effects of abnormal and normalized tumor angiogenesis state on the immune environment, but summarizes the latest progress of immunotherapy combined with anti-angiogenic therapy. We hope this review provides an applied reference for anti-angiogenesis drugs and synergistic immunotherapy therapy.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1198972